BR112021020777A2 - Vacina de subunidade do csfv - Google Patents
Vacina de subunidade do csfvInfo
- Publication number
- BR112021020777A2 BR112021020777A2 BR112021020777A BR112021020777A BR112021020777A2 BR 112021020777 A2 BR112021020777 A2 BR 112021020777A2 BR 112021020777 A BR112021020777 A BR 112021020777A BR 112021020777 A BR112021020777 A BR 112021020777A BR 112021020777 A2 BR112021020777 A2 BR 112021020777A2
- Authority
- BR
- Brazil
- Prior art keywords
- present
- csfv
- immunogenic composition
- subunit vaccine
- protein
- Prior art date
Links
- LXWYCLOUQZZDBD-LIYNQYRNSA-N csfv Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LXWYCLOUQZZDBD-LIYNQYRNSA-N 0.000 title abstract 3
- 229940031626 subunit vaccine Drugs 0.000 title abstract 2
- 241001465754 Metazoa Species 0.000 abstract 4
- 230000002163 immunogen Effects 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 208000001726 Classical Swine Fever Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0601—Invertebrate cells or tissues, e.g. insect cells; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/76—Agarose, agar-agar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Abstract
vacina de subunidade do csfv. a presente invenção refere-se ao campo da saúde animal. em particular, a presente invenção refere-se a uma proteína e2 recombinante da peste suína clássica compreendendo pelo menos uma mutação no epitopo especificamente reconhecido pelo anticorpo monoclonal 6b8. ainda, a presente invenção apresenta uma composição imunogênica compreendendo a proteína e2 recombinante da presente invenção e o uso da composição imunogênica para a prevenção e/ou o tratamento de doenças associadas ao csfv em um animal. além disso, a presente invenção apresenta um método e um kit para distinguir animais infectados com csfv de animais vacinados com a composição imunogênica da presente invenção.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019083198 | 2019-04-18 | ||
| PCT/CN2020/085037 WO2020211802A1 (en) | 2019-04-18 | 2020-04-16 | Csfv subunit vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021020777A2 true BR112021020777A2 (pt) | 2021-12-14 |
Family
ID=72837038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021020777A BR112021020777A2 (pt) | 2019-04-18 | 2020-04-16 | Vacina de subunidade do csfv |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220193221A1 (pt) |
| EP (1) | EP3956438A4 (pt) |
| JP (1) | JP2022529062A (pt) |
| KR (1) | KR20220009959A (pt) |
| CN (1) | CN113677792A (pt) |
| AU (1) | AU2020260237A1 (pt) |
| BR (1) | BR112021020777A2 (pt) |
| CA (1) | CA3137194A1 (pt) |
| CL (1) | CL2021002727A1 (pt) |
| MX (1) | MX2021012695A (pt) |
| WO (1) | WO2020211802A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111116720B (zh) * | 2020-02-24 | 2022-02-15 | 中牧实业股份有限公司 | 一种猪瘟病毒重组e2蛋白及其应用 |
| CN116547296A (zh) * | 2020-10-19 | 2023-08-04 | 勃林格殷格翰动物保健(中国)有限公司 | 重组经典猪瘟病毒e2蛋白 |
| TW202332684A (zh) | 2021-10-19 | 2023-08-16 | 中國大陸商勃林格殷格翰動物保健（中國）有限公司 | 具有ｂ／ｃ結構域交換的重組經典豬瘟病毒ｅ２蛋白 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8063195B2 (en) * | 2009-05-22 | 2011-11-22 | The United States Of America As Represented By The Secretary Of Agriculture | Mutations in a toll-like receptor motif in the NS4B of classical swine fever virus strain brescia influences virulence in swine |
| CN109182380B (zh) * | 2018-08-14 | 2022-06-03 | 浙江大学 | 杆状病毒表达的猪瘟e2亚单位疫苗的制备方法及应用 |
| CN110029116B (zh) * | 2019-03-12 | 2022-09-13 | 华南农业大学 | 一种分泌表达多抗原表位猪瘟病毒e2基因的重组病毒及制备方法与应用 |
| CN110157681A (zh) * | 2019-05-25 | 2019-08-23 | 青岛易邦生物工程有限公司 | 一种猪瘟e2蛋白亚单位疫苗 |
| CN116547296A (zh) * | 2020-10-19 | 2023-08-04 | 勃林格殷格翰动物保健(中国)有限公司 | 重组经典猪瘟病毒e2蛋白 |
-
2020
- 2020-04-16 KR KR1020217037477A patent/KR20220009959A/ko unknown
- 2020-04-16 MX MX2021012695A patent/MX2021012695A/es unknown
- 2020-04-16 EP EP20792227.9A patent/EP3956438A4/en active Pending
- 2020-04-16 CA CA3137194A patent/CA3137194A1/en active Pending
- 2020-04-16 US US17/604,295 patent/US20220193221A1/en active Pending
- 2020-04-16 BR BR112021020777A patent/BR112021020777A2/pt unknown
- 2020-04-16 JP JP2021561929A patent/JP2022529062A/ja active Pending
- 2020-04-16 WO PCT/CN2020/085037 patent/WO2020211802A1/en unknown
- 2020-04-16 CN CN202080028485.9A patent/CN113677792A/zh active Pending
- 2020-04-16 AU AU2020260237A patent/AU2020260237A1/en active Pending
-
2021
- 2021-10-18 CL CL2021002727A patent/CL2021002727A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021012695A (es) | 2022-01-31 |
| EP3956438A4 (en) | 2023-01-18 |
| US20220193221A1 (en) | 2022-06-23 |
| EP3956438A1 (en) | 2022-02-23 |
| CA3137194A1 (en) | 2020-10-22 |
| JP2022529062A (ja) | 2022-06-16 |
| KR20220009959A (ko) | 2022-01-25 |
| AU2020260237A1 (en) | 2021-11-25 |
| WO2020211802A1 (en) | 2020-10-22 |
| CN113677792A (zh) | 2021-11-19 |
| CL2021002727A1 (es) | 2022-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021020777A2 (pt) | Vacina de subunidade do csfv | |
| MD3601358T2 (ro) | Anticorpi anti-TREM2 și metode de utilizare a acestora | |
| BR112017003194B8 (pt) | Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição | |
| EA201790342A1 (ru) | Антитела к trem2 и способы их применения | |
| BR112018074978A2 (pt) | anticorpos para alfa-sinucleína e usos dos mesmos | |
| BR112019005587A2 (pt) | proteínas de ligação recombinantes e sua utilização | |
| EA201900562A1 (ru) | Бис-октагидрофенантрена карбоксамиды и их белковые конъюгаты | |
| BR112014020019A2 (pt) | vetores poxvirais recombinantes expressando tanto proteínas da raiva e ox40 e vacinas feitos a partir destes | |
| CL2021000089A1 (es) | Anticuerpos anti -sortilina y métodos para su uso. | |
| CL2020002012A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032) | |
| AR114565A1 (es) | Proteínas de fusión fc il-22 y métodos de uso | |
| NZ766003A (en) | Factor h binding protein variants and methods of use thereof | |
| EA202192606A1 (ru) | Антитела к пироглутамат--амилоиду и их применение | |
| BR112017002173A2 (pt) | anticorpos semelhantes à angiopoietina e métodos de uso | |
| CO2020012621A2 (es) | Composiciones de proteína de fusión recombinante neuregulina-1 (nrg-1) humana y métodos para su uso | |
| BR112022011885A2 (pt) | Molécula de ácido nucleico, composição imunogênica, peptídeo, e, métodos para induzir uma resposta imune e para tratar ou prevenir uma patologia | |
| TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
| ECSP20076576A (es) | Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas | |
| MX2017011480A (es) | Anticuerpo de anti-esclerostina, fragmento de union a antigeno y uso medico del mismo. | |
| PH12019502449A1 (en) | Anti-jagged1 antigen binding proteins | |
| BR112018010494A2 (pt) | proteínas de fusão fmdv e e2 e seus usos | |
| EA201892524A1 (ru) | Днк-моноклональные антитела, нацеленные на il-6 и cd126 | |
| BR112022014821A2 (pt) | Tratamento envolvendo vacinação de antígeno e ligação de agentes que se liga a pd-l1 e cd137 | |
| BR112022002236A2 (pt) | Composições, composições farmacêuticas e uso das mesmas para tratar câncer, bem como formulações que compreendem as mesmas | |
| BR112016024742A2 (pt) | método para a seleção de uma proteína, proteínas de ligação ao antígeno, anticorpos, imunoconjugado, formulação farmacêutica, uso do anticorpo, ácido nucleico e polipeptídeo |